Acute myeloid leukemia with variant t(8;10;21)

Barbora Bacova; Jiri Sobotka; Petra Kacirkova; Veronika Rivnacova; Ivana Karlova/Zubata; Jan Novak

doi:10.1016/j.lrr.2022.100350

Acute myeloid leukemia with variant t(8;10;21)

Leuk Res Rep. 2022 Sep 15:18:100350. doi: 10.1016/j.lrr.2022.100350. eCollection 2022.

Authors

Barbora Bacova¹, Jiri Sobotka², Petra Kacirkova³, Veronika Rivnacova¹, Ivana Karlova/Zubata¹, Jan Novak^{1

4}

Affiliations

¹ Department of Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady. Srobarova 50, 100 34, Prague 10, Czech Republic.
² Laboratory of Medical Genetics, SPADIA LAB a.s., Ostrava, Czech Republic.
³ Central laboratories of the Faculty Hospital Kralovske Vinohrady, Czech Republic.
⁴ Department of Immunology, 3rd Faculty of Medicine, Charles University. Ruska 87, 100 00, Prague 10, Czech Republic.

Abstract

The t(8;21)(q22;q22) is one of the most common chromosomal abnormalities in acute myeloid leukemia (AML). Approximately 3-4% of AML cases are associated with additional chromosomal abnormalities. Their impact on the prognosis of the disease remains to be established. Here we report a case of t(8;10;21) AML with mutated c-KIT that shared key morphological features with classical t(8;21) leukemias, including the M2 morphology pattern and CD34, HLA-DR phenotype. The 63-year-old female was treated with two inductioncontaining Daunoribicine and Cytarabine and four cycles of intermediate-dose Cytarabine (1.5 g/m²) and achieved long-lasting remission.

Keywords: 21); Acute myeloid leukemia; Cytogenetics; Fluorescence in situ hybridization; t(8.

Publication types

Case Reports